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Abstract
Background: Visceral leishmaniasis (VL) is characterized by parasite-specific immunosuppression besides an intense pro-
inflammatory response. Lipopolisaccharide (LPS) has been implicated in the immune activation of T-cell deficient diseases
such as HIV/AIDS and idiopathic lymphocytopenia. The source of LPS is gram-negative bacteria that enter the circulation
because of immunological mucosal barrier breakdown. As gut parasitization also occurs in VL, it was hypothesized that LPS
may be elevated in leishmaniasis, contributing to cell activation.
Methodology/Principal Findings: Flow cytometry analysis and immunoassays (ELISA and luminex micro-beads system)
were used to quantify T-cells and soluble factors. Higher LPS and soluble CD14 levels were observed in active VL in
comparison to healthy subjects, indicating that LPS was bioactive; there was a positive correlation between these molecules
(r=0.61;p,0.05). Interestingly, LPS was negatively correlated with CD4
+ (r=20.71;p,0.01) and CD8
+ T-cells
(r=20.65;p,0.05). Moreover, higher levels of activation-associated molecules (HLA-DR, CD38, CD25) were seen on T
lymphocytes, which were positively associated with LPS levels. Pro-inflammatory cytokines and macrophage migration
inhibitory factor (MIF) were also augmented in VL patients. Consistent with the higher immune activation status, LPS levels
were positively correlated with the inflammatory cytokines IL-6 (r=0.63;p,0.05), IL-8 (r=0.89;p,0.05), and MIF
(r=0.64;p,0.05). Also, higher plasma intestinal fatty acid binding protein (IFABP) levels were observed in VL patients,
which correlated with LPS levels (r=0.57;p,0.05).
Conclusions/Significance: Elevated levels of LPS in VL, in correlation with T-cell activation and elevated pro-inflammatory
cytokines and MIF indicate that this bacterial product may contribute to the impairment in immune effector function. The
cytokine storm and chronic immune hyperactivation status may contribute to the observed T-cell depletion. LPS probably
originates from microbial translocation as suggested by IFABP levels and, along with Leishmania antigen-mediated immune
suppression, may play a role in the immunopathogenesis of VL. These findings point to possible benefits of antimicrobial
prophylaxis in conjunction with anti-Leishmania therapy.
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Introduction
Visceral leishmaniasis (VL) is a protozoan infection caused in
Brazil by Leishmania (Leishmania) infantum chagasi. This disease
represents an important worldwide public health problem and
affects around 4,000 new cases per year in Brazil [1]. The parasite
has a tropism to lymphoid organs, including the bone marrow,
spleen, lymph nodes, and liver [2], which explains the immune
abnormalities commonly found in affected patients.
VL is a systemic disease with a very complex host-parasite
relationship. The parasite affects mainly cells of the macrophage
lineage and induces, to some extent, deviations in the production
of erythrocytes, platelets, and lymphocytes, consequently generat-
ing anemia, thrombocytopenia, and decreased T-cell count [2].
The active phase of VL is characterized by an impairment of the
specific effector T-cell response to leishmanial antigens, the
absence of a delayed-type hypersensitivity reaction to parasite
antigens and a decreased lymphocyte proliferative response, as
well as the absence or low levels of interferon (IFN)-c and
interleukin (IL)-2 cytokine production after in vitro stimulation of
mononuclear cells with Leishmania antigens [3,4,5]. Elevated type 2
cytokine production has been detected in the serum of VL patients
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of anti-leishmanial antibody titers are markers of this disease [2].
Restoration of the immune response to L. chagasi, as assessed by
IFN-c production and lymphocyte proliferation, has been
observed following specific treatment [9,10].
Interestingly, despite the severe impairment of the Leishmania-
specific effector immune response, a number of typical markers of
chronic activation of the immune system have paradoxically been
detected. High levels of pro-inflammatory and anti-inflammatory
cytokines have been observed during active disease, but cytokine
production returns to normal upon successful chemotherapy
[8,10,11]. Although there is evidence that components of the
parasite play a critical role in determining the immunological
abnormalities observed in VL patients, the precise mechanisms
underlying these alterations remain unknown [2,11,12].
Chronic immune activation has been observed in some
infectious and non-infectious diseases, which can contribute to
immune suppression and further progression of such illnesses. As
an example, infection by human immunodeficiency virus type 1
(HIV-1) induces chronic immune activation and leads to a severe
suppression of the T lymphocyte compartment, caused mainly by
CD4
+ T-cell depletion [13]. Early CD4
+ T-cell depletion in the
gastrointestinal tract of HIV-1-infected patients can cause a breach
in the integrity of the mucosal immune system, enabling
translocation of luminal microbial products into the circulation
[14,15]. Bacterial components such as lipopolisaccharide (LPS)
stimulate the adaptive and innate immune system, creating an
inflammatory environment that results in a high turnover of T-cell
populations, eventually leading to systemic immune impairment
[16]. Such a phenomenon can be indirectly detected by measuring
LPS plasma levels and has also been observed in conditions such
as inflammatory bowel disease [17], idiopathic CD4 lymphocyto-
penia [18], and prior to hematopoietic transplantation [19].
LPS stimulates mononuclear cells via Toll-like receptor (TLR)-4
and promotes the secretion of a variety of inflammatory soluble
factors such as IFN-c, IL-1, IL-6, tumor necrosis factor (TNF)-a,
and macrophage migration inhibitory factor (MIF) [20,21]. MIF
occurs pre-formed and is rapidly released from many cell types in
response to different stimuli, including endotoxemia [22]. MIF has
also been implicated as a critical factor in the pathogenesis of a
variety of inflammatory diseases [23,24] such as sepsis [25,26],
tuberculosis [27], dengue fever [28], and HIV-1 infection [29].
This enhancement of intestinal permeability which results from
mucosal damage and can potentially permits microbial transloca-
tion and lead to systemic activation has been assessed by plasma
levels of intestinal fatty acid binding protein (IFABP). This
cytosolic protein is expressed in the epithelium of small intestine,
being released when the cell membrane integrity is compromised
[30], such as in patients with abdominal trauma [31] and celiac
disease [32].
Our hypothesis was that immunosuppression may also affect the
gut mucosal barrier in VL, enabling translocation of microbial
products into the systemic circulation. Therefore, we investigated
whether plasma LPS levels were increased in VL patients, and the
possible association with lymphocyte functions. For these purpos-
es, quantization of T-cell subsets, cell activation status, pro-
inflammatory cytokine and MIF, as well as LPS, and IFABP levels
were measured in clinical samples from patients with VL.
Materials and Methods
Patients and healthy subjects
Ten VL patients were enrolled in this study. Six were males,
and the age of the patients ranged between 18 and 60 years
(37619 years). Five patients had active disease without previous
anti-Leishmania therapy, and 5 patients were evaluated after being
cured. Additionally, 2 of the 5 patients with active disease were
also subjected to post-therapy evaluation. VL diagnosis was
confirmed by identification of amastigotes directly visualized in
cells of Giemsa-stained bone marrow smears. Eight healthy
subjects (HS) were included as controls; five were males, and the
ages ranged between 24 and 32 years (27.263 years). They
presented a negative proliferative response in vitro to antigens of L.
chagasi. Neither of the VL patients or healthy subjects presented
HIV-1 infection, or any other co-morbidities. Patients were treated
for VL according to the Brazilian Ministry of Health guidelines
[1].
Ethics statement
This study was approved by the Ethics Committee of the
Universidade Federal do Mato Grosso do Sul and by the Ethics
Committee of the Fundac ¸a ˜o Oswaldo Cruz. Written informed
consent was obtained from all participants prior to blood
collection.
Immunologic assessments
CD4
+ and CD8
+ blood T lymphocytes were quantified by using
a BD TritestH monoclonal antibody specific for CD4, CD8, and
CD3 conjugated to fluorescein isothiocyanate (FITC), phycoery-
thrin (PE), and peridinin chlorophyll protein (PerCP), respectively,
and the BDTrue Count reagent kit was used (BD Biosciences,
Franklin Lakes, NJ, USA). Samples were acquired using a
FACSCalibur (BD Biosciences, USA) and analyzed by Multiset
software (BD, USA). The results are expressed as the number of
cells/mm
3.
To evaluate lymphocyte activation, peripheral blood mononu-
clear cells were obtained by centrifugation over a gradient of
Author Summary
Visceral leishmaniasis (VL) affects organs rich in lympho-
cytes, being characterized by intense Leishmania-induced
T-cell depletion and reduction in other hematopoietic
cells. In other infectious and non-infectious diseases in
which the immune system is affected, such as HIV-AIDS
and inflammatory bowel disease, damage to gut-associat-
ed lymphocyte tissues occurs, enabling luminal bacteria to
enter into the circulation. Lipopolisaccharide (LPS) is a
bacterial product that stimulates macrophages, leading to
the production of pro-inflammatory cytokines and other
soluble factors such as MIF, which in turn activate
lymphocytes. Continuous and exaggerated stimulation
causes exhaustion of the T-cell compartment, contributing
to immunosuppression.
Herein, we show that an increment in LPS plasma levels
also occurs in VL; the higher the LPS levels, the lower the
TCD4
+ and TCD8
+ cell count in the blood. This T-cell
depletion may affect the mucosal immune system, which,
along with intestinal parasitization by amastigotes, may
contribute to gut barrier damage and consequent
microbial translocation. LPS levels were correlated with
T-cell activation, pro-inflammatory cytokine plasma levels,
MIF, and IFABP, showing that a bacterial molecule,
probably from luminal origin, not associated with Leish-
mania infection can negatively affect the immune system.
These findings points to possible benefits of antimicrobial
prophylaxis in conjunction with anti-Leishmania therapy.
LPS in Visceral Leishmaniasis
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Louis, MO, USA). Cells (10
5 per tube) were stained with the
following monoclonal antibody pairs: anti-CD8 FITC/anti-CD38
PE, anti-CD3 FITC/anti-HLA-DR PE (BD Simultest; BD
Biosciences, San Jose, CA, USA), and anti-CD4 PE-Cy5/anti-
CD25 PE (BD Biosciences Pharmigen, California, USA). After
incubation, the cells were fixed with phosphate-buffered saline plus
1% paraformaldehyde and analyzed by flow cytometry. At least
10,000 events were acquired using a FACSCalibur (BD Biosci-
ences, CA, USA), and phenotypic analysis was carried out by using
CellQuest software (BD Biosciences, USA). Results are shown as
the percentage of CD3
+ T, CD4
+ T, and CD8
+ T cells expressing
HLA-DR, CD25, and CD38 on the membrane surface,
respectively. Schematic flow cytometry analysis of T lymphocytes
activation-associated molecules is provided in Figure S1 (HLA-
DR, CD38, CD25).
Quantification of LPS, soluble CD14 (sCD14) and IFABP
plasma levels
Plasma samples were collected after centrifugation of heparin-
ized venous blood, which was aliquoted and stored at 270uC until
the analysis. These samples were diluted in endotoxin-free water,
and plasma LPS was quantified by a commercial assay kit
(Limulus amebocyte lysate QCL-1000; Cambrex, Milan, Italy)
according to the manufacturer’s protocol. The results are
expressed as pg/mL and the minimum detected level was
10 pg/mL. The endotoxin levels were measured in leishmanial
lysate to exclude any possibility of cross reaction between LPS and
Leishmania derived LPS-like molecules. Plasma levels of sCD14
were measured using enzyme-linked immunosorbent assay
(ELISA) assays (sCD14 Quantikine; R&D Systems, Minneapolis,
MN, USA); the results are expressed as ng/mL and the minimum
detected level was 125 pg/mL. Plasma IFABP levels were
determined using a human highly specific ELISA commercial kit
(Duo Set; RD Systems, USA). The results are expressed as pg/mL
and the detection limit was 31.2 pg/mL.
Cytokine measurement
A multiplex biometric immunoassay containing fluorescent
dyed microbeads was used for plasma cytokine measurement (Bio-
Rad Laboratories, Hercules, CA, USA). The following cytokines
were quantified: IFN-c, TNF, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8,
IL-10, IL-12, IL-13, IL-17, MCP-1 and MIP-1b; cytokine levels
were calculated by Luminex technology (Bio-Plex Workstation;
Bio-Rad Laboratories, USA). The analysis of data was performed
using software provided by the manufacturer (Bio-Rad Laborato-
ries, USA). A range of 0.51–8,000 pg/mL recombinant cytokines
was used to establish standard curves and the sensitivity of the
assay.
Plasma levels of MIF were measured using an ELISA
commercial kit (Duo Set; RD Systems, USA), and the results are
expressed as pg/mL; the minimum detected level was 31.2 pg/
mL.
Statistical analysis
The Mann-Whitney test was used to compare data between
groups, and correlations between different parameters were
analyzed using the non-parametric Spearman’s test. Statistical
analysis was confirmed by the Kruskall-Wallis method. Analysis
was performed with GraphPad Prism (GraphPad Software version
4.0 for Windows; San Diego, CA, USA). Data were presented as
mean 6 standard deviation and median. Differences were
considered significant when p,0.05.
Results
Considering that LPS is implicated in the pathogenesis of
several immunodeficiency diseases, we examined whether an
increment in LPS would also be a prevalent phenomenon in VL.
Significantly higher mean levels of LPS were found in the plasma
of VL patients (4163.0 pg/mL, median=41.5 pg/mL, n=5)
compared to HS (2368.0 pg/mL, median=26 pg/mL, n=8;
p,0.01, Figure 1A). A tendency towards decreased LPS levels
(3566.0 pg/mL, median=34.3 pg/mL, n=7) was seen after
therapy, although the levels were still higher than those observed
in HS (Figure 1A).
Since it is known that LPS binds to monocytes/macrophages
through the CD14 receptor and promotes the release of sCD14 [17],
we measured plasma sCD14 levels to indirectly determine whether the
LPS in the patients’ blood was biologically active. VL patients
presented increased levels of sCD14 (active VL: 5,44861,359 ng/mL,
median=5,133 ng/mL, n=5) relative to HS (2,4706815 ng/mL,
median=2,555 ng/mL, n=8; p,0.01). Decreased levels of sCD14
(3,4916712 ng/mL, median=3,556 ng/mL, n=7; p,0.05) were
observed in the remission phase inc o m p a r i s o nt ob e f o r et h e r a p y
(Figure 1B). In addition, a significant correlation between LPS and
sCD14 plasma levels (r=0.61; p,0.05) was found, suggesting that
LPS-induced cell stimulation can contribute to sCD14 secretionin vivo.
Further, the repercussions of the LPS increment on lymphocyte
effector function were assessed by analyzing T-cell subset counts
and cell activation status. Significantly lower numbers of CD4
+ T
cells (3616200 cells/mm
3, median=426 cells/mm
3, n=5) and
CD8
+ T cells (1966142 cells/mm
3, median=223 cells/mm
3,
n=5) were observed during active disease in comparison to HS
(TCD4
+=1,1186175 cells/mm
3, median=1,106 cells/mm
3;T C
D8
+=6496230 cells/mm
3, median=583 cells/mm
3,n = 8 ;p,
0.05). After treatment, a partial recovery of T-cell counts was
observed (TCD4
+=7276160 cells/mm
3, median=727 cells/
mm
3; TCD8
+=5556166 cells/mm
3, median=456 cells/mm
3,
n=7; p,0.05) in parallel to a satisfactory therapeutic response
(Figure 2A and 2B). Active VL patients had a negative proliferative
response in vitro to L. chagasi antigens (data not shown).
Higher mean levels of cellular activation were detected in VL
patients, independently of the clinical phase of leishmaniasis, when
compared to HS (p,0.05, Figure 2E and 2F). However, patients in
the active phase had the highest percentage of TCD3
+HLA-DR
+
cells (22.3614%, median=18%) and TCD4
+CD25
+ cells (386
20%, median=31.5%) when compared to HS (TCD3
+HLA-DR
+:
6.864.3%, median=5.5%; TCD4
+CD25
+: 16.865%, medi-
an=16.5%). Interestingly, the levels of TCD8
+CD38
+ cells (active
VL=40618.5%, median=40.5%; remission=4567.3%, median
=45.4%) were also augmented in VL patients (HS: 3164.4%,
median=33%).
To understand whether the elevated LPS levels may be involved
in the altered cellular activation status and lymphocyte counts seen
in VL patients, correlation analyses were performed. Absolute
counts of CD4
+ (r=20.71; p,0.01) and CD8
+ T cells (r=20.65;
p,0.05) were negatively correlated with LPS (Figure 2C and 2D),
showing that the lower T subset numbers were associated with the
highest LPS levels during the active phase of leishmaniasis,
whereas during clinical remission, the inverse was observed, i.e.,
the higher T CD4
+ counts were associated with the lowest LPS
levels. Additionally, a significant positive correlation between
plasma LPS levels and the frequency of cells with an activated
phenotype, i.e., CD3
+HLA-DR
+ (r=0.58; p,0.05) and CD4
+
CD25
+ (r=0.60; p,0.05) T cells, was also found (Figure 2G and
2H).
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www.plosntds.org 3 July 2011 | Volume 5 | Issue 7 | e1198Figure 1. Plasma levels of lipopolysaccharide (LPS) and soluble CD14 in patients with visceral leishmaniasis (VL). Increased LPS (A)
and sCD14 (B) levels in VL patients. Correlation between LPS and sCD14 levels in VL patients (C). Active VL patients (solid squares), VL patients in
remission (solid triangles), and healthy subjects (solid diamonds). Each point represents 1 subject. The horizontal bars indicate the median value.
doi:10.1371/journal.pntd.0001198.g001
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LPS is the secretion of pro-inflammatory molecules. To under-
stand whether this process also occurs in VL patients, cytokine
concentrations were measured in the plasma of these patients.
Similar to T-cell activation, plasma levels of pro-inflammatory
cytokines were also elevated in VL patients, not only during active
disease, but also up to 6 months after the end of therapy relative to
HS (Table 1).
As LPS also stimulates the secretion of MIF, this molecule
was also investigated. MIF was significantly elevated in active
VL (33,18067,273 pg/mL; median=32,000 pg/mL, n=5)
when compared either with patients during clinical remis-
sion (19,34867,690 pg/mL; median=15,600 pg/mL, n=7) or
with HS (7,40063,763 pg/mL; median=6,238 pg/mL, n=8;
Figure 3A). Even in the remission phase, MIF levels were still
increased in comparison to HS (p,0.05). Consistent with the
higher immune activation status, plasma LPS levels were positively
correlated with the inflammatory cytokines IL-6 (r=0.63;
p,0.05), IL-8 (r=0.89; p,0.05), and MIF (r=0.64; p,0.05)
(Figure 3B, C, and D). The augmented MIF secretion, which
correlated with LPS levels, may contribute to the enhanced LPS
stimulation in these patients, due to the ability of MIF to up-
regulate the cellular expression of TLR-4 [22].
Finally, we assessed the plasmatic IFABP levels, since this protein is
released into the circulation on intestinal cell injury. VL patients
showed higher levels of IFABP (9446484 pg/mL; median=
918 pg/mL, n=5) in comparison to HS (223.46133 pg/mL;
median=234 pg/mL, n=8; p,0.05, Figure 4A). The highest
plasma IFABP values were observed during active disease, while
remission VL patients presented decreased levels (8096299 pg/mL;
median=794 pg/mL, n=7). A positive correlation was verified
between IFABP and LPS levels (r=0.57; p,0.05),which maysuggest
some intestinal damage (Figure 4B).
Discussion
Several circulating molecules that act as soluble receptors for
IL-2 [33], immunocomplexes, and lipoproteins [34] have been
implicated in VL pathogenesis, but have not been proven to
mediate immunosuppressive activity. In this study, it was
demonstrated that LPS levels were elevated in VL patients in
association with T-cell depletion, lymphocyte activation, and pro-
inflammatory cytokine elevation, providing evidence that this
factor may play a role in VL immunopathogenesis.
The elevated levels of plasma LPS detected in VL patients
indicate that this substance may have a systemic biological effect.
It is known that LPS acts via the TLR-4/CD14 receptor complex,
leading to sCD14 secretion by monocytes/macrophages [17].
Thus, the elevated levels of sCD14 observed in VL patients in this
study indicate that LPS was bioactive in these patients.
Furthermore, LPS was positively correlated with sCD14 levels,
reinforcing the idea that this microbial product could also
contribute to cell activation mechanisms in VL.
Although suppression of the immune response is a hallmark
mechanism associated with the development of VL, VL patients
present with systemic immune activation as a consequence of pro-
inflammatory cytokine release [8,11,35,36,37]. In this study, it was
verified that T lymphocytes up-regulated surface HLA-DR,
CD38, and CD25 levels, independently of the clinical phase of
VL. These results show that T lymphocytes are also activated in
VL, as has been demonstrated in other immunosuppressive
diseases such as HIV/AIDS [13,38]. On the other hand, high
lymphocyte activation can lead to death by apoptosis, thereby
reducing the number of these cells [2,11,12]. In fact, the lowest
counts of CD4
+ and CD8
+ T cells were observed in patients with
active VL, whereas recovery was marked by an increase in the
number of these T-cells, which is probably related to the
development of an effector response [8,9,37]. However, inasmuch
as increased levels of these T-cell subsets has been observed during
clinical remission, i.e., after successful therapy, these cell counts
Figure 2. T-cell subset levels and their activation status in patients with visceral leishmaniasis (VL). A. Absolute counts of CD4
+ T
lymphocytes. B. Absolute counts of CD8
+ T lymphocytes. Correlation between lipopolysaccharide (LPS) plasma levels and the absolute counts of CD4
+
T lymphocytes (C) and absolute counts of CD8
+ T lymphocytes (D) in VL patients. E. Levels of HLA-DR
+ on CD3
+ T lymphocytes. F. Levels of CD25
+ on
CD4
+ T lymphocytes. Correlation between LPS plasma levels and percentage of TCD3
+ cells expressing membrane HLA-DR
+ (G) and percentage of
TCD4
+ cells expressing membrane CD25
+ (H) in VL patients. Active VL patients (solid squares), VL patients in remission (solid triangles), and healthy
subjects (solid diamonds). Each point represents 1 subject. The horizontal bars indicate the median value.
doi:10.1371/journal.pntd.0001198.g002
Table 1. Pro-inflammatory cytokine levels in the plasma of
patients with visceral leishmaniasis (VL).
Cytokines
pg/mL
Active VL
patients
(n=5)
VL patients
in remission
(n=7)
Healthy
subjects
(n=8) p value* p value**
IFN-c 1,143
(454–4,446)
783
(367–3,482)
19
(5.3–145)
0.010 0.0010
TNF 143.5
(37.7–555)
100
(57.3–589)
2
(1.5–8.5)
0.001 0.0006
IL-2 35.3
(27–38.5)
62
(27.6–435)
6
(1–9)
0.001 0.0003
IL-6 416
(211–557)
49
(30–115)
1
(0.3–2.5)
0.004 0.0007
IL-8 8,000
(1,887–13,578)
4,325
(427–8,988)
2.5
(1.5–3.0)
0.008 0.0050
IL-1b 9.7
(4–226)
7.5
(2–138)
0.5
(0.4–0.6)
0.001 0.0010
IL-17 288
(102–398)
193.5
(131–627)
2
(2–16)
0.002 0.0006
IL-4 42.3
(29.2–54.7)
35.0
(23.7–59.1)
5.0
(5–12.5)
0.007 0.0020
IL-5 9.4
(3.0–143)
2.9
(2.6–8.1)
0.4
(0.1–1.8)
0.030 0.0300
IL-10 13
(8.7–54.8)
12.6
(6.0–66)
1.0
(0.1–1.6)
0.001 0.0003
IL-12 16.6
(10.5–27)
34.0
(20.9–44.8)
1.0
(0.8–1.4)
0.004 0.0010
IL-13 5.8
(3.8–33)
8.3
(3.0–12)
1.1
(0.7–1.5)
0.001 0.0020
MCP-1 538
(285.7–606)
402
(327–966.8)
52
(31–95.8)
0.004 0.0003
MIP-1b 730.3
(418–3,363)
571.5
(426–1,111)
14.3
(0.1–50)
0.001 0.0010
IFN: interferon, IL: interleukin, TNF: tumor necrosis factor, MCP1: monocyte
chemoattractant protein-1, MIP: macrophage inflammatory protein-1b.
Statistical analysis was performed using the Mann-Whitney test (*,**) and
confirmed by the Kruskall-Wallis method.
Data are presented as median (interquartile range).
*Between active VL patients and healthy subjects.
**Between VL patients in remission and healthy subjects.
doi:10.1371/journal.pntd.0001198.t001
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demonstrated [8,37].
Interestingly, LPS levels in VL patients were negatively
correlated with the absolute T CD4
+ and T CD8
+ cells counts,
showing that higher LPS levels were associated with a lower
number of T-cell subsets. In addition, a positive correlation
between ex vivo cellular activation, represented by HLA-DR and
CD25 molecules in T-cells, and plasma LPS levels was found.
Firstly, considering that LPS stimulates macrophages to release
pro-inflammatory factors such as IL-8, IL-1b, TNF-a, IL-6, and
MIF [39], which in turn activate T-cells, it is conceivable that the
presence of LPS in the blood stream may contribute to the
compromised T-lymphocyte effector function in VL. Secondly, it
may be hypothesized that, along with leishmanial antigens, LPS
may also contribute to the elevated cellular immune activation in
VL. In turn, this activation status can indirectly contribute to the
impairment of T cell counts by a mechanism of cell death due to
intense stimulation, as has been suggested in other infectious or
non-infectious diseases [16,17]. Even considering the negative
correlation results between T cell counts and LPS levels, the
approach utilized in this study do not allow a definitive conclusion
regarding the causality between these parameters.
The VL patients studied here presented with a cytokine storm
characterized by increased levels of pro-inflammatory (IFN-c,
TNF-a, IL-2, IL-6, IL-12, IL-17, and MIF), anti-inflammatory
(IL-4, IL-5, and IL-13), and regulatory cytokines (IL-10) and
chemokines (IL-8, MCP, and MIP-1b). These findings are similar
to those for sepsis [26] and severe dengue fever [40]. Our results
also reinforce early data in which a mixed cytokine profile was
observed during VL disease [7,8,10,41,42]. The factors that lead
to this systemic activation are still largely unknown. Our data
suggest that LPS may play a role in this effect.
It is interesting to note that LPS levels were positively correlated
with MIF, a pleiotropic cytokine released after cell exposure to
microbial products [39] or to pro-inflammatory cytokines [42]. It
is known that MIF up-regulates the expression of TLR-4, the
Figure 3. Plasma cytokine levels in visceral leishmaniasis (VL) patients and their association with lipopolysaccharide (LPS) levels. A.
Plasma macrophage migration inhibitory factor (MIF) levels in VL patients. Correlation between LPS plasma levels and MIF production (B), IL-6
production (C), and IL-8 production (D) in VL patients. Active VL patients (solid squares), VL patients in remission (solid triangles), and healthy subjects
(solid diamonds). Each point represents 1 subject. The horizontal bars indicate the median value.
doi:10.1371/journal.pntd.0001198.g003
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production of inflammatory cytokines such as IL-6 and IL-8
[39,43]. Therefore, MIF production may contribute to the
inflammatory milieu in VL patients and the enhancement in the
susceptibility to LPS stimulation. As observed for the frequency of
T-cells with an activated phenotype, IL-6 and IL-8 levels were also
correlated with LPS. In septic patients, high MIF levels have been
considered indicative of poor outcome, highlighting the potential
therapeutic benefits of MIF neutralization [26]. Our results show
that LPS may be contributing not only to the activation of
circulating cells, but also to the inflammatory environment
observed in VL patients, which may worsen the prognosis.
Although LPS levels were lower after VL treatment, it remained
higher than those in HS, as also observed for the other
immunological parameters investigated. These results indicate
that, despite the return of good general clinical status, the
reestablishment of immune response homeostasis takes longer to
occur. Alternatively, we should considerate that elevated LPS
levels could be due to reduced LPS clearance by the kidneys.
The source of the microbial product LPS in the blood stream of
VL patients needs to be elucidated. Although, bacterial infections
are common complications in VL, none of the patients included in
this study presented clinical evidence of such infection. Consid-
ering that systemic T-cell depletion can also affect gut-associated
lymphoid tissues, as has been suggested for other immunosup-
pressive pathologies [18], one can suggest the hypothesis that
microbial translocation into the blood circulation may also occur
in VL. More importantly, gut damage has been extensively
documented in VL patients [44–46], and cells are heavily
parasitized by Leishmania amastigotes due to parazitation of
mucosal cells, causing frequent diarrhea [45] that is likely to
affect the function of this innate barrier. The elevated levels of
IFABP, an important plasma marker of gut injury, indicate that
intestinal permeability is increased in these patients. Thus, we
believe that a vicious circle can be occurring in VL patients, in
which systemic inflammation and cellular activation of VL per se
[7,8,11,41] contributes to gut damage, leading to microbial
translocation which in turn increase or sustain the systemic
Figure 4. Plasma levels of intestinal fatty acid binding protein (IFABP) in visceral leishmaniasis patients. A. Elevated IFABP levels in VL
patients. (B) Correlation between IFABP and LPS levels in VL patients. Active VL patients (solid squares), VL patients in remission (solid triangles), and
healthy subjects (solid diamonds). Each point represents 1 subject. The horizontal bars indicate the median value.
doi:10.1371/journal.pntd.0001198.g004
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previously been described in graft-versus-host disease [19],
inflammatory bowel disease [17], and idiopathic lymphocytopenia
[18]. In the context of infectious diseases, microbial translocation
demonstrated in HIV-1 infection is associated with LPS-induced
systemic immune activation, which indirectly affects the progres-
sion toward AIDS [16].
In summary, the present data show that LPS is elevated in VL
and possibly contributes, along with Leishmania antigens, to the
cytokine storm and immune activation status in this pathology. In
this context, plasma LPS may be a biomarker suitable for assessing
VL prognosis. Considering that LPS originates from gram-
negative bacteria from the gut and may reach the blood stream
after crossing the gut, the use of antimicrobial prophylaxis in
conjunction with anti-Leishmania therapy may be beneficial for VL
patients, as this strategy may reduce LPS-mediated immune
activation in VL.
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